BiovaxID mantle cell lymphoma trial data to be presented in June

Biovest.jpg

Biovest International, makers of the personalized therapeutic lymphoma vaccine BiovaxID, have announced that data from the company's Phase II mantle cell lymphoma clinical trial will be presented by the National Cancer Institute at the upcoming 2012 American Society of Clinical Oncology Annual Meeting in June (ASCO 2012).

The Phase II trial was also conducted by researchers at the National Cancer Institute.

The presentation's abstract is titled "Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL)" and will be presented by the NCI on Saturday, June 2nd at McCormick Place in Chicago.

"We continue to be very proud of the NCI's long-term commitment to the development of this important personalized cancer vaccine," stated Biovest's President & CEO, Samuel S. Duffey, Esq. "We look forward to commenting on this new BiovaxID clinical trial data when ASCO lifts the embargo."

Source: MarketWatch

LymphomaInfo Social